# Human Bioequivalence Study of Amphotericin B Liposome for Injection

> **NCT06977490** · NA · COMPLETED · sponsor: **Sichuan Huiyu Pharmaceutical Co., Ltd** · enrollment: 42 (actual)

## Conditions studied

- Invasive Fungal Infections
- Neutropenic Fever
- Visceral Leishmaniasis

## Interventions

- **DRUG:** Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.)
- **DRUG:** Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)

## Key facts

- **NCT ID:** NCT06977490
- **Lead sponsor:** Sichuan Huiyu Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-13
- **Primary completion:** 2025-10-07
- **Final completion:** 2025-10-07
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-11-25

## Collaborators

- Changsha King-eagle Med Technology Co., Ltd.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06977490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06977490, "Human Bioequivalence Study of Amphotericin B Liposome for Injection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06977490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*